Century Therapeutics (IPSC) news

Recent news

Century Therapeutics Q2 operating income USD -36.527 million vs. IBES estimate USD -24.5 million

AInvest Wire · Aug 12, 2026

Mizuho initiates coverage on Century Therapeutics Inc with outperform rating; target price $8

Mizuho Securities has initiated coverage on Century Therapeutics Inc. (NASDAQ: IPSC) with an "Outperform" rating and a price target of $8.00 , according to a recent report. The stock currently trades at $2.17, giving the company a market capitalization of $391 million. Analysts have previously set…

AInvest Wire · Jun 4, 2026

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by